EVOS

Use case · Public data only

Half the revenue was heading off patent. The evidence showed what would replace it.

In 2018, three medicines carried about half of Roche Pharmaceuticals' revenue, and all three were losing patent protection. We read Roche's public pipeline and patent record to see whether the replacements were already there. Seven years later, we checked.

The franchise handoff

Big Three, 2018CHF 21.0bn
Big Three, FY2025CHF 3.2bn
Five successors, FY2025CHF 21.4bn
This is not a customer story. Roche has not used EVOS and has no relationship with Rapid Alpha. This use case applies the method EVOS is built on to public filings, patent records and Roche's published results, to show what that evidence can tell you about any company.
CHF 21.0bn → 3.2bn
the three blockbusters, 2018 to FY2025
CHF 44.0bn → 47.7bn
Roche Pharmaceuticals still grew
7 of 10
FY2025 best sellers from the engine the data flagged
~7 years
how far ahead the method read the revenue mix

A gap of known size, years in advance

Avastin, Herceptin and Rituxan made up roughly USD 21 billion, about half of Roche Pharmaceuticals' 2018 revenue. On Roche's own assumption of 60–70% biosimilar erosion, sales were expected to fall by about CHF 13 billion. This is the situation EVOS is built for: a growth commitment, a hole of known size, and a question about what fills it.

2018 revenue, three medicinesabout USD 21bn
Expected fall (60 to 70% erosion)about CHF 13bn

The replacements were in the pipeline before they were in the revenue

We coded every molecule entering Roche's pipeline from 2008 to 2018 by who originated it, how Roche accessed it (build, partner or buy) and when it came in. Three things stood out: Genentech originated 32% of new molecules and 49% in oncology; most entered at Phase 1, when cost is lowest; and Roche's success rate was about 8%, against roughly 4% for the industry.

Access mode, 162 new molecules

Build58%
Partner33%
Buy9%

Entry stage

Entered at Phase 1about 86%
Several of the replacements had no approval at all in 2018. The column simply read “None”.

The lost franchise wasn't defended. It was replaced.

By FY2025 the three blockbusters had dropped out of Roche's top ten. Five successor medicines brought in CHF 21.4 billion, and Roche Pharmaceuticals grew to CHF 47.7 billion. Ocrevus and Vabysmo, in the neurology and ophthalmology positions the 2018 data flagged, are now among its largest products.

PlaceholderChart: top ten medicines by originator, color-coded Genentech / Chugai / partner (from the RA report)

The same method, built into the platform

Roche is not an EVOS customer.

What we did with Roche public informationWhere it lives in EVOSWhat it shows
Sized the revenue at risk from expiring patentsFocus: growth goals and gapYour gap, as a number and a date
Coded every pipeline asset by origin, access mode and stageEvidence and RegistriesYour opportunities, each with a source
Compared build, partner and buy routesFocus: scenario plansOptions side by side against one goal
Tracked patent filings and partner activitySignalsAlerts when the evidence moves
Checked the prediction against reported revenueResultsActuals against plan, re-forecast early

What this does and doesn't prove

This is one company and one seven-year window, and the predictions matched. It is not a back-tested signal with a measured hit rate across many companies. We say so on purpose: the discipline that makes the method worth trusting is the same one that declines to overclaim it.

Your company has a public record too

Bring one product line. We'll show you what the evidence says about where your next revenue will come from, and the gap if it doesn't.

FAQ

Is Roche an EVOS customer?

No. This use case is built entirely from public sources and implies no relationship with Roche or Genentech.

Does this only work in pharma?

The patent-cliff mechanics are specific to pharma. The method (reading where growth will come from in the evidence before it shows in revenue) applies to any technical company.

Who did the analysis?

Matthew Wahlrab (Rapid Alpha) and Christian Hartmann (RWS), published as Accessing Innovation, Parts 1 (2022) and 2 (2026).